Familial Adenomatous Polyposis Market to Witness Growth Through 2036 Driven by Precision Medicine and Emerging Chemopreventive Therapies | DelveInsight

DelveInsight's "Familial Adenomatous Polyposis Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of the FAP, historical and forecasted epidemiology, as well as FAP market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Explore the intricate details of the Familial Adenomatous Polyposis Market Report @ https://www.delveinsight.com/report-store/familial-adenomatous-polyposis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Familial Adenomatous Polyposis Market Report
• In July 2026, Parabilis Medicines, Inc. announced result of A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors.
• In June 2026, Recursion Pharmaceuticals Inc. announced result of A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokintetics, and Pharmacodynamics of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP).
• The Familial Adenomatous Polyposis Market Dynamics are expected to evolve significantly during the forecast period, driven by increasing genetic screening, improved identification of APC gene mutations, greater surveillance of at-risk individuals, and the development of novel chemopreventive therapies.
• According to estimates, the United States accounted for the largest Familial Adenomatous Polyposis Therapeutics Market among the 7MM in 2025.
• Regional market dynamics show the United States leading in revenue, while Japan and Europe demonstrate steady growth, driven by rising FAP prevalence, improved diagnostics, and increasing adoption of advanced therapies.
• As per Kindie et al. (2024), FAP occurs in approximately 1/10,000 to 1/30,000 live births and accounts for less than 1% of all colorectal cancers in the US.
• According to Chung et al. (2024), FAP has an estimated prevalence of 1 in 8,000 to 1 in 18,000 and accounts for less than 1 percent of all colorectal cancers in the US, affecting males and females equally with a worldwide distribution.
• The Familial Adenomatous Polyposis Companies include Emtora Biosciences, Biodexa, Recursion, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, Allakos, and others.
• Promising Familial Adenomatous Polyposis Therapies include eRAPA and REC-4881, among others.

Get a Free sample for the Familial Adenomatous Polyposis Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/familial-adenomatous-polyposis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Familial Adenomatous Polyposis?
Familial Adenomatous Polyposis (FAP) is a rare, inherited autosomal dominant colorectal cancer predisposition syndrome caused primarily by pathogenic mutations in the APC (adenomatous polyposis coli) gene. The condition is characterized by the development of hundreds to thousands of adenomatous polyps throughout the large intestine, typically beginning during adolescence or early adulthood. If left untreated, individuals with classic FAP face an almost 100% lifetime risk of developing colorectal cancer, often before the age of 40-50 years. In addition to colorectal manifestations, patients may develop extracolonic features, including duodenal and gastric polyps, desmoid tumors, osteomas, congenital hypertrophy of the retinal pigment epithelium (CHRPE), thyroid cancer, hepatoblastoma, and other benign or malignant tumors, imposing a substantial lifelong clinical burden that requires intensive surveillance, preventive interventions, and multidisciplinary management.

Familial Adenomatous Polyposis Epidemiology Segmentation in the 7MM
• Total Familial Adenomatous Polyposis Diagnosed Prevalent Cases
• Familial Adenomatous Polyposis Mutation-specific Diagnosed Prevalent Cases
• Total Familial Adenomatous Polyposis Treated Cases

Download the report to understand which factors are driving Familial Adenomatous Polyposis epidemiology trends @ https://www.delveinsight.com/report-store/familial-adenomatous-polyposis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Familial Adenomatous Polyposis Treatment Landscape
Currently, there are no approved pharmacological therapies for FAP. Management is primarily aimed at preventing colorectal cancer, controlling polyp burden, and monitoring extracolonic manifestations through regular endoscopic surveillance, pharmacologic therapy, prophylactic surgery, and long-term follow-up. For most patients, prophylactic colectomy or proctocolectomy remains the standard of care, often followed by ongoing endoscopic surveillance of the remaining gastrointestinal tract. Off-label pharmacologic options, including NSAIDs such as Sulindac and selective COX-2 inhibitors like Celecoxib, may help reduce polyp burden and delay disease progression but are not curative.

Familial Adenomatous Polyposis Pipeline Analysis
• eRAPA: Emtora Biosciences/Biodexa Pharmaceuticals
eRAPA is a proprietary oral capsule formulation of rapamycin (sirolimus), an mTOR inhibitor, currently in a pivotal Phase III trial (SERENADE), supported by a USD 17 million grant from the Cancer Prevention Research Institute of Texas (CPRIT) and a Company match of USD 8.5 million. Anticipated US launch: 2029.

• REC-4881: Recursion Pharmaceuticals
REC-4881 is an orally bioavailable, non-ATP-competitive, allosteric small-molecule inhibitor of MEK1 and MEK2, being developed to reduce polyp burden and progression to adenocarcinoma in people living with FAP, currently in the Phase I/II TUPELO study and holding FDA Fast Track Designation.

Familial Adenomatous Polyposis Companies
Emtora Biosciences, Biodexa, Recursion, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, Allakos, and others

Discover more about therapies set to grab major Familial Adenomatous Polyposis market share @ https://www.delveinsight.com/sample-request/familial-adenomatous-polyposis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Familial Adenomatous Polyposis Market Outlook
The Familial Adenomatous Polyposis therapeutics market is projected to grow steadily during the forecast period, supported by increasing awareness of hereditary colorectal cancer syndromes, broader genetic screening, and advances in molecular diagnostics that enable earlier detection. Current management primarily relies on regular surveillance, prophylactic surgery, and chemopreventive agents to reduce cancer risk. However, these approaches do not fully prevent disease progression or eliminate the long-term burden of treatment. The emergence of targeted therapies, including eRAPA and REC-4881, is expected to transform the treatment landscape by addressing significant unmet medical needs.

Scope of the Familial Adenomatous Polyposis Market Report
• Study Period: 2022-2036
• Historical Year: 2022-2025
• Forecast Period: 2026-2036
• Base Year: 2026
• Coverage: 7MM (US; Germany, France, Italy, Spain, UK; Japan)
• Familial Adenomatous Polyposis Companies: Emtora Biosciences, Biodexa, Recursion, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, Allakos, and others
• Familial Adenomatous Polyposis Therapies: Sulindac, Celecoxib (CELEBREX), eRAPA, REC-4881, and others
• Familial Adenomatous Polyposis Epidemiology Segmentation: Total Diagnosed Prevalent Cases, Mutation-specific Diagnosed Prevalent Cases, Total Treated Cases
• Analysis: KOL Views, SWOT Analysis, Reimbursement, Conjoint Analysis, Unmet Need, Market Drivers and Barriers, Epidemiology Patient Burden

To know more about Familial Adenomatous Polyposis companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/familial-adenomatous-polyposis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology of Familial Adenomatous Polyposis
6. Familial Adenomatous Polyposis Market Overview at a Glance
7. Disease Background and Overview of Familial Adenomatous Polyposis
8. Epidemiology and Patient Population of Familial Adenomatous Polyposis
9. Patient Journey of Familial Adenomatous Polyposis
10. Emerging Drugs
11. Familial Adenomatous Polyposis: 7MM Analysis
12. Unmet Needs of Familial Adenomatous Polyposis
13. SWOT Analysis of Familial Adenomatous Polyposis
14. KOL Views of Familial Adenomatous Polyposis
15. Market Access and Reimbursement of Familial Adenomatous Polyposis
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.